A double-blind, Randomized, Controlled trial comparison of a topical piroxicom plus metronidazole gel and Piroxicom gel in Treatment for Periodontal disease.

Comparison of a topical piroxicom plus metronidazole gel and piroxicom gel in treatment for pockets in chronic periodontal Disease.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014050817587N3

Enrollment

Registered

2014-06-26

Start date

2013-01-14

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal disesaes. Periodontal disesaes

Interventions

Intervention 1: piroxicam ( 5 percent made of Razak Pharmaceutical Co -Iran ) plus metronidazole (7.5%) (made of Pars Pharmaceutical Co-Iran ) with an insulin syringe is placed into the periodonta

Treatment - Drugs

piroxicam ( 5 percent made of Razak Pharmaceutical Co -Iran ) plus metronidazole (7.5%) (made of Pars Pharmaceutical Co-Iran ) with an insulin syringe is placed into the periodontal pocket.

Piroxicam gel ( 5 percent made of Razak Co-Iran ) with an insulin syringe is placed into the periodontal pocket.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All of the Patients following criteria were included in the study: aged between 30 and 45 years; 20 natural teeth present; Probing depth (PD) of 4-6 mm) Patients were Excluded from the Study if they met one or more of the Following criteria: Existing systemic disease that may influence the severity or progression of periodontitis, or Diabetes Mellitus; Taking medications that may influence the periodontium (e.g. Phenytoin, ... or Non-steroidal anti-Inflammatory drugs) or other medicines (Antibiotic) within the 6 months preceding the beginning of the study, Orthodontic treatments; Extensive dental restorations, Pregnancy or Lactation; Non-agreement with the examination and treatment appointments; Mouthrinses, During the entire period of the Study; Hypersensitive to these medicine; Smoking

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pocket depth. Timepoint: Reduction of Pocket depth. Method of measurement: Periodontal probe.;Clinical attachment level. Timepoint: 15 days. Method of measurement: Periodontal probe.	—

Secondary

Measure	Time frame
Reduction of bleeding on probing. Timepoint: 15 days. Method of measurement: Periodontal probe.;Reduction of plaque index. Timepoint: 15 days. Method of measurement: Plaque Index(O’Leary ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirhossein Farahmand

Dental Branch Islamic Azad University of Tehran

perio-implant@hotmail.com+98 21 2284 9604

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026